GlassScriptPhysician profile
Marcus R Rovira
NPI 1568455905
$8,900.26
in general payments reported to CMS, 2019-2025
35 companies · $4,146 in 2025
The $4,146 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $214 · 2023: $1,888 · 2024: $2,507 · 2025: $4,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,210 · Travel and Lodging: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,210.21 |
| Travel and Lodging | $329.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,452.01 | 2021-2025 | |
| Enterra Medical, INC. | $1,458.15 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $766.99 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.23 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $390.65 | 2023-2024 | Zeposia |
| Madrigal Pharmaceuticals | $369.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $314.62 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $313.79 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $298.96 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $286.94 | 2023-2025 | Sucraid, Sucraid |
| Pfizer INC. | $252.86 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $218.80 | 2023-2025 | Ocaliva |
| Ardelyx, INC. | $196.06 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $147.03 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $144.34 | 2024-2025 | Zenpep, Vowst |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $123.46 | 2024 | Brixadi |
| Ipsen Biopharmaceuticals, INC | $103.83 | 2025 | Iqirvo |
| Fujifilm Healthcare Americas Corporation | $96.64 | 2023 | Utaswako Afp-L3 |
| Ironwood Pharmaceuticals, INC | $88.22 | 2023-2024 | Linzess |
| Evoke Pharma, INC. | $76.48 | 2023-2025 | Gimoti |
| Genentech USA, INC. | $52.14 | 2021-2022 | |
| Lilly USA, LLC | $48.73 | 2024 | Omvoh |
| Celltrion USA INC. | $47.18 | 2025 | Vegzelma |
| Novo Nordisk INC | $37.33 | 2025 | Wegovy |
| Medtronic, INC. | $35.79 | 2023 | Gi Genius |
| Ferring Pharmaceuticals INC. | $33.30 | 2023 | Rebyota |
| Redhill Biopharma INC. | $29.52 | 2023 | Movantik, Talicia, Aemcolo |
| Glaxosmithkline, LLC. | $16.26 | 2022 | |
| Braintree Laboratories, INC. | $14.98 | 2023 | Suflave |
| Biohaven Pharmaceuticals, INC. | $14.78 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.27 | 2021 | |
| Genzyme Corporation | $13.47 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.25 | 2023 | Cyltezo |
| Biohaven Pharmaceutical Holding Company LTD. | $13.04 | 2022 | |
| Exact Sciences Corporation | $12.84 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Rovira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.